IODIDE ION I-131

First approved in 1951

Details

Stereochemistry	ACHIRAL
Molecular Formula	I
Molecular Weight	130.9061
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	-1

SHOW SMILES / InChI

Structure Search

SMILES

[131I-]

InChI

InChIKey=XMBWDFGMSWQBCA-RNFDNDRNSA-M

InChI=1S/HI/h1H/p-1/i1+4

HIDE SMILES / InChI

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021305s027lbl.pdf | https://www.drugbank.ca/drugs/DB09293

Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Therapeutic solutions of Sodium Iodide-131 are indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodine. Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodine. It is also indicated for use in performance of the radioactive iodide (RAI) uptake test to evaluate thyroid function. Taken orally, sodium iodide I-131 is rapidly absorbed and distributed within the extracellular fluid of the body. The iodide is concentrated in the thyroid via the sodium/iodide symporter, and subsequently oxidized to iodine. The destruction of thyroidal tissue is achieved by the beta emission of sodium iodide I-131.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
hyperthyroidism 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016515s016lbl.pdf	Primary		Approved 8429	SODIUM IODIDE I 131 Approved Use Sodium Iodide I 131 is indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodide. Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodide. Launch Date 1971
thyroid carcinomas 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016515s016lbl.pdf	Primary		Approved 8429	SODIUM IODIDE I 131 Approved Use Sodium Iodide I 131 is indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodide. Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodide. Launch Date 1971

Sample Use Guides

In Vivo Use Guide

The recommended dosage for orally administered Sodium Iodide I 131 Capsule USP is based on the thyroid gland uptake as well as the size of the gland. Thyroidal uptake and size should be determined by the physician prior to treatment and may be useful in calculating the therapeutic dose to be administered to the individual patient. Recommended dosages of orally administered Sodium Iodide I-131 are: Disease therapy: Antihyperthyroid Therapy: Oral dose of 148 to 370 megabecquerels (4 to 10 millicuries). Toxic nodular goiters and other serious thyroid conditions may require larger dosages. Antineoplastic – Ablation of normal thyroid tissue: Initial oral dose of 1.1 to 3.7 gigabecquerels (30 to 100 millicuries).Subsequent ablation of metastases with oral dose of 3.7 to 7.4 gigabecquerels (100 to 200 millicuries).

Route of Administration: Oral

Name

Type

Language

IODIDE ION I-131

Common Name

English

IODIDE-131

Common Name

English

IODIDE I-131 ION

Common Name

English

IODIDE ION, I-131

Common Name

English

IODIDE I-131

Common Name

English

IODIDE ION I 131

Common Name

English

RADIOIODINE

Common Name

English

IODIDE (131I-)

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175872